Fresh from the reapproval of Roche/Genentech’s Susvimo, positive readouts for sustained release implants, and suprachoroidal delivery revolutionizing gene therapy delivery to the retina, matching the right delivery route to the right drug has become an unavoidable topic for ophthalmology biopharma.

The 3rd Ophthalmic Drug Delivery Summit is the premier gathering for the industry to discuss and explore innovations and future directions for ophthalmic device and formulation development. Delve into the latest in-depth analysis of intravitreal, subretinal, suprachoroidal and topical delivery and explore advancements in ophthalmic pharmacology.

With an ever-growing market opportunity, the industry is in an arms race to demonstrate the clinical benefits of longer lasting efficacy and less invasive drug delivery through alternative administration routes and novel ocular devices. Reuniting 60+ ophthalmic delivery innovators in sunny San Francisco, the 3rd Ophthalmic Drug Delivery Summit is the only industry-focused meeting dedicated to translating more efficacious, longer lasting, and less invasive retinal delivery. Across 3 jam-packed days, join clinical and preclinical ocular experts, ophthalmic device engineers, product development leaders and formulation specialists to delve a range of ocular drug-delivery systems striving to maintain drug concentrations, reduce dosage frequency, and overcome ocular barriers.

This meeting is your one-stop-shop to gather key updates on cutting-edge technologies, ophthalmic pharmacology and to compare routes of administration capabilities to overcome anatomical barriers, enhance bioavailability, and improve patient outcomes such as:

• Optimizing sustained release formulations and release kinetics to fine-tune dosing for long-lasting retinal delivery with Genentech, Ocular and Alcon
• Evaluating the durability and safety of delivering drugs to the retina via suprachoroidal delivery with Everads, Genentech and Clearside
• Utilizing gene therapy transduction via sub retinal and para retinal delivery to the retina with REGENXBIO, GelMEDIX and Ray Therapeutics
• Troubleshooting species differences and biocompatibility with ocular models to accelerate delivery translation with Genentech and Wake Forest University
• Overcoming clinical trial hurdles and achieving operational synergies to streamline development with Aviceda, AbbVie and Regeneron

Don’t miss this exclusive opportunity to meet world class ophthalmic delivery experts from the likes of Genentech, AbbVie, Bayer, Clearside Biomedical, Ocular Therapeutix, REGENXBIO, Regeneron, Eyepoint Pharmaceuticals, and more.